US3096248A
(en)
*
|
1959-04-06 |
1963-07-02 |
Rexall Drug & Chemical Company |
Method of making an encapsulated tablet
|
US3406178A
(en)
*
|
1964-02-04 |
1968-10-15 |
Monsanto Chem Australia Ltd |
Preparation of 2-substituted benzimidazoles
|
US3362956A
(en)
*
|
1965-08-19 |
1968-01-09 |
Sterling Drug Inc |
1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
|
US4200641A
(en)
*
|
1976-12-21 |
1980-04-29 |
Janssen Pharmaceutica, N.V. |
1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
|
FI791926A
(fi)
|
1978-06-20 |
1979-12-21 |
Synthelabo |
Fenylpiperazinderivat
|
DE3000979A1
(de)
*
|
1980-01-12 |
1981-07-23 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
|
DE3126703A1
(de)
|
1981-07-07 |
1983-01-27 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Bromhexin-retardform und verfahren zu ihrer herstellung
|
JPS58134033A
(ja)
|
1982-02-02 |
1983-08-10 |
Fujisawa Pharmaceut Co Ltd |
医薬組成物
|
IT1176613B
(it)
*
|
1984-08-14 |
1987-08-18 |
Ravizza Spa |
Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
|
IE58370B1
(en)
|
1985-04-10 |
1993-09-08 |
Lundbeck & Co As H |
Indole derivatives
|
GB8607294D0
(en)
*
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
DE3620643A1
(de)
|
1985-06-22 |
1987-01-22 |
Sandoz Ag |
Thiazole, ihre herstellung und verwendung
|
HUT43600A
(en)
*
|
1985-06-22 |
1987-11-30 |
Sandoz Ag |
Process for production of new thiazole derivatives and medical compound containing those
|
GB8601160D0
(en)
*
|
1986-01-17 |
1986-02-19 |
Fujisawa Pharmaceutical Co |
Heterocyclic compounds
|
US5036088A
(en)
*
|
1986-06-09 |
1991-07-30 |
Pfizer Inc. |
Antiallergy and antiinflammatory agents, compositions and use
|
JPH0784462B2
(ja)
*
|
1986-07-25 |
1995-09-13 |
日清製粉株式会社 |
ベンゾイミダゾ−ル誘導体
|
US4968508A
(en)
*
|
1987-02-27 |
1990-11-06 |
Eli Lilly And Company |
Sustained release matrix
|
US4792452A
(en)
*
|
1987-07-28 |
1988-12-20 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
GB8830312D0
(en)
|
1988-12-28 |
1989-02-22 |
Lundbeck & Co As H |
Heterocyclic compounds
|
US4954503A
(en)
*
|
1989-09-11 |
1990-09-04 |
Hoechst-Roussel Pharmaceuticals, Inc. |
3-(1-substituted-4-piperazinyl)-1H-indazoles
|
WO1992002215A1
(en)
|
1990-08-09 |
1992-02-20 |
Massachusetts Institute Of Technology |
Method for treating the premenstrual or late luteal phase syndrome
|
EP0497985B1
(en)
|
1990-08-24 |
1998-07-22 |
Shin-Etsu Chemical Co., Ltd. |
Coating base for pharmaceutical film and production thereof
|
NZ241613A
(en)
*
|
1991-02-27 |
1993-06-25 |
Janssen Pharmaceutica Nv |
Highlighting intagliations in tablets
|
SE9100860D0
(sv)
*
|
1991-03-22 |
1991-03-22 |
Kabi Pharmacia Ab |
New use
|
FR2675800A1
(fr)
|
1991-04-26 |
1992-10-30 |
Rhone Poulenc Rorer Sa |
Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant.
|
HUT68769A
(en)
|
1991-05-07 |
1995-07-28 |
Merck & Co Inc |
FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
|
IT1251144B
(it)
*
|
1991-07-30 |
1995-05-04 |
Boehringer Ingelheim Italia |
Derivati del benzimidazolone
|
US5407686A
(en)
*
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
DE4216364A1
(de)
|
1991-12-14 |
1993-11-25 |
Thomae Gmbh Dr K |
Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
US5225417A
(en)
*
|
1992-01-21 |
1993-07-06 |
G. D. Searle & Co. |
Opioid agonist compounds
|
US5492907A
(en)
*
|
1992-12-09 |
1996-02-20 |
The United States Of America As Represented By The Department Of Health & Human Services |
Antipsychotic composition and method of treatment
|
DE69429768T2
(de)
|
1993-04-05 |
2002-09-19 |
Competitive Technologies, Inc. |
Diagnose und behandlung von erektilen funktionsstörungen
|
FR2707294B1
(fr)
*
|
1993-07-06 |
1995-09-29 |
Pf Medicament |
Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
|
GB9401090D0
(en)
|
1994-01-21 |
1994-03-16 |
Glaxo Lab Sa |
Chemical compounds
|
DE69523155T2
(de)
|
1994-06-14 |
2002-02-07 |
Pfizer Inc., New York |
Benzimidazolonderivate mit zentraler dopaminerger aktivität
|
KR100397082B1
(ko)
|
1994-08-23 |
2004-02-11 |
스미스크라인 비참 피.엘.시. |
이부프로펜및코데인을함유하는약제제형
|
ATE247114T1
(de)
|
1994-09-12 |
2003-08-15 |
Lilly Co Eli |
Serotonergische modulatoren
|
JPH08143476A
(ja)
|
1994-11-18 |
1996-06-04 |
Japan Tobacco Inc |
薬物放出制御膜及び固形製剤
|
FR2727682A1
(fr)
*
|
1994-12-02 |
1996-06-07 |
Pf Medicament |
Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
|
US5552412A
(en)
*
|
1995-01-09 |
1996-09-03 |
Pfizer Inc |
5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
|
US5883094A
(en)
*
|
1995-04-24 |
1999-03-16 |
Pfizer Inc. |
Benzimidazolone derivatives with central dopaminergic activity
|
US5854290A
(en)
*
|
1995-09-21 |
1998-12-29 |
Amy F. T. Arnsten |
Use of guanfacine in the treatment of behavioral disorders
|
US6083947A
(en)
*
|
1996-01-29 |
2000-07-04 |
The Regents Of The University Of California |
Method for treating sexual dysfunctions
|
GB9613423D0
(en)
|
1996-06-26 |
1996-08-28 |
Lilly Industries Ltd |
Pharmaceutical compounds
|
US5916916A
(en)
*
|
1996-10-10 |
1999-06-29 |
Eli Lilly And Company |
1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
|
AU5179898A
(en)
|
1996-11-06 |
1998-05-29 |
Sharmatek, Inc. |
Delayed delivery system for acid-sensitive drugs
|
EP0942728A1
(en)
*
|
1996-12-02 |
1999-09-22 |
MERCK SHARP & DOHME LTD. |
Use of nk-1 receptor antagonists for treating sexual dysfunction
|
US5859246A
(en)
|
1997-01-30 |
1999-01-12 |
Neurogen Corporation |
1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
|
US20040023948A1
(en)
*
|
1997-03-24 |
2004-02-05 |
Green Richard David |
Fast-dispersing dosage form containing 5-HT1 agonists
|
GB9706089D0
(en)
|
1997-03-24 |
1997-05-14 |
Scherer Ltd R P |
Pharmaceutical composition
|
IL133405A0
(en)
*
|
1997-06-11 |
2001-04-30 |
Procter & Gamble |
Film-coated tablet for improved upper gastrointestinal tract safety
|
EP0901787B1
(en)
*
|
1997-09-10 |
2003-05-28 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
SE9703375D0
(sv)
|
1997-09-18 |
1997-09-18 |
Astra Ab |
A new combination
|
CH692199A8
(fr)
|
1997-10-09 |
2002-06-14 |
Cermol S.A. |
Composes pyridiques et compositions pharmaceutique
|
JP3724157B2
(ja)
*
|
1997-10-30 |
2005-12-07 |
コニカミノルタホールディングス株式会社 |
映像観察装置
|
FR2775188B1
(fr)
*
|
1998-02-23 |
2001-03-09 |
Lipha |
Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
|
WO1999059584A1
(en)
|
1998-05-20 |
1999-11-25 |
Schering Corporation |
Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
|
EP1077704A4
(en)
|
1998-05-21 |
2002-01-30 |
Lilly Co Eli |
COMBINATION THERAPY FOR TREATING DEPRESSION
|
US20020151543A1
(en)
*
|
1998-05-28 |
2002-10-17 |
Sepracor Inc. |
Compositions and methods employing R (-) fluoxetine and other active ingredients
|
CA2334551A1
(en)
|
1998-06-11 |
1999-12-16 |
Merck & Co., Inc. |
Spiropiperidine derivatives as melanocortin receptor agonists
|
US6068846A
(en)
*
|
1998-08-05 |
2000-05-30 |
Melaleuca, Incorporated |
Methods and materials for treating depression and mood disorder
|
EP0982030A3
(en)
*
|
1998-08-17 |
2000-05-10 |
Pfizer Products Inc. |
2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
|
UA67802C2
(uk)
|
1998-10-23 |
2004-07-15 |
Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. |
Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
|
WO2000028993A1
(en)
|
1998-11-19 |
2000-05-25 |
Nortran Pharmaceuticals, Inc. |
Serotonin ligands as pro-erectile compounds
|
US6680071B1
(en)
*
|
1999-03-03 |
2004-01-20 |
R. P. Scherer Technologies, Inc. |
Opioid agonist in a fast dispersing dosage form
|
WO2000063189A1
(en)
|
1999-04-16 |
2000-10-26 |
Novo Nordisk A/S |
Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
|
AU5259100A
(en)
|
1999-04-28 |
2000-11-10 |
Respiratorius Ab |
Medicament
|
IT1312310B1
(it)
|
1999-05-07 |
2002-04-15 |
Recordati Ind Chimica E Farma |
Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
|
US6579968B1
(en)
|
1999-06-29 |
2003-06-17 |
Palatin Technologies, Inc. |
Compositions and methods for treatment of sexual dysfunction
|
US20030055070A1
(en)
|
1999-07-01 |
2003-03-20 |
Wilma Harrison |
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
|
US6346548B1
(en)
*
|
1999-08-16 |
2002-02-12 |
Cephalon, Inc. |
Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
|
IT1313625B1
(it)
|
1999-09-22 |
2002-09-09 |
Boehringer Ingelheim Italia |
Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
|
CN1660435A
(zh)
*
|
2000-02-24 |
2005-08-31 |
法玛西雅厄普约翰美国公司 |
新的药物联合形式
|
AU2001260548A1
(en)
|
2000-06-28 |
2002-01-08 |
Pfizer Products Inc. |
Melanocortin receptor ligands
|
US6960597B2
(en)
|
2000-06-30 |
2005-11-01 |
Orth-Mcneil Pharmaceutical, Inc. |
Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
|
US20020052370A1
(en)
|
2000-07-06 |
2002-05-02 |
Barber Christopher Gordon |
Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
|
US20040198706A1
(en)
|
2003-03-11 |
2004-10-07 |
Carrara Dario Norberto R. |
Methods and formulations for transdermal or transmucosal application of active agents
|
US6521623B1
(en)
*
|
2000-09-19 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
|
US6586435B2
(en)
*
|
2000-09-19 |
2003-07-01 |
Boehringer Ingelheim Pharma Kg |
Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
|
DE60123643T2
(de)
|
2000-09-19 |
2007-08-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Benzimidazolonderivate mit affinität zu serotonin- und dopaminrezeptoren
|
CZ20031458A3
(cs)
|
2000-11-22 |
2004-02-18 |
Abbott Laboratories |
Léčivo pro léčení sexuální dysfunkce savce
|
GB0105893D0
(en)
|
2001-03-09 |
2001-04-25 |
Pfizer Ltd |
Pharmaceutically active compounds
|
GB0106446D0
(en)
|
2001-03-15 |
2001-05-02 |
Vernalis Res Ltd |
Chemical compounds
|
OA12553A
(en)
|
2001-03-28 |
2006-06-07 |
Pfizer |
N-Phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD.
|
DK1256343T3
(da)
|
2001-05-11 |
2006-10-30 |
Juergen K Dr Beck |
Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
|
US6627646B2
(en)
*
|
2001-07-17 |
2003-09-30 |
Sepracor Inc. |
Norastemizole polymorphs
|
CA2453609C
(en)
|
2001-07-18 |
2010-05-04 |
Merck & Co., Inc. |
Bridged piperidine derivatives as melanocortin receptor agonists
|
CA2455987C
(en)
|
2001-07-30 |
2010-06-29 |
Neotherapeutics, Inc. |
Tetrahydroindolone and purine derivatives linked to arylpiperazines
|
PL210224B1
(pl)
|
2001-08-02 |
2011-12-30 |
Bidachem Spa |
Krystaliczna odmiana polimorficzna flibanseryny, sposób jej wytwarzania, jej zastosowanie, oraz kompozycje farmaceutyczne ją zawierające
|
US7183410B2
(en)
*
|
2001-08-02 |
2007-02-27 |
Bidachem S.P.A. |
Stable polymorph of flibanserin
|
US20030060475A1
(en)
*
|
2001-08-10 |
2003-03-27 |
Boehringer Ingelheim Pharma Kg |
Method of using flibanserin for neuroprotection
|
DE10138273A1
(de)
|
2001-08-10 |
2003-02-27 |
Boehringer Ingelheim Pharma |
Arzneimittel mit neuroprotektiver Wirkung
|
HUP0202719A3
(en)
|
2001-08-21 |
2006-01-30 |
Pfizer Prod Inc |
Pharmaceutical compositions for the treatment of female sexual dysfunctions
|
DE10149674A1
(de)
|
2001-10-09 |
2003-04-24 |
Apogepha Arzneimittel Gmbh |
Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
DE10209982A1
(de)
|
2002-03-07 |
2003-09-25 |
Boehringer Ingelheim Pharma |
Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
|
US20040048877A1
(en)
*
|
2002-05-22 |
2004-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions containing flibanserin
|
CA2483597C
(en)
|
2002-05-22 |
2010-02-09 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New pharmaceutical compositions containing flibanserin polymorph a
|
AU2003268026A1
(en)
|
2002-07-30 |
2004-02-16 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
US20040116532A1
(en)
*
|
2002-09-13 |
2004-06-17 |
Craig Heacock |
Pharmaceutical formulations of modafinil
|
US20040132697A1
(en)
*
|
2002-11-06 |
2004-07-08 |
Pfizer Inc. |
Treatment of female sexual dysfunction
|
GB0225908D0
(en)
|
2002-11-06 |
2002-12-11 |
Pfizer Ltd |
Treatment of female sexual dysfunction
|
US20040147581A1
(en)
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
WO2004063864A2
(en)
*
|
2003-01-06 |
2004-07-29 |
Laura Berman |
Method and system for computerized sexual function assessment of female users
|
US20050004105A1
(en)
*
|
2003-01-29 |
2005-01-06 |
Emer Leahy |
Treatment for a attention-deficit hyperactivity disorder
|
US20050037983A1
(en)
|
2003-03-11 |
2005-02-17 |
Timothy Dinan |
Compositions and methods for the treatment of depression and other affective disorders
|
WO2005007166A1
(en)
|
2003-07-16 |
2005-01-27 |
Pfizer Limited |
Treatment of sexual dysfunction
|
US20050065158A1
(en)
*
|
2003-07-16 |
2005-03-24 |
Pfizer Inc. |
Treatment of sexual dysfunction
|
CA2537837A1
(en)
*
|
2003-09-11 |
2005-03-24 |
Xenoport, Inc. |
Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
|
WO2005044238A1
(en)
|
2003-11-07 |
2005-05-19 |
Ranbaxy Laboratories Limited |
Modified release solid dosage form of amphetamine salts
|
KR20070014184A
(ko)
|
2004-04-22 |
2007-01-31 |
베링거 인겔하임 인터내셔날 게엠베하 |
성기능 장애 치료용 신규 약제학적 조성물 ⅱ
|
US20050239798A1
(en)
|
2004-04-22 |
2005-10-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for the treatment of premenstrual and other female sexual disorders
|
US20060014757A1
(en)
*
|
2004-07-14 |
2006-01-19 |
Boehringer Ingelheim Pharmaceuticals |
Method for the treatment of anorexia nervosa
|
US20060025420A1
(en)
*
|
2004-07-30 |
2006-02-02 |
Boehringer Ingelheimn International GmbH |
Pharmaceutical compositions for the treatment of female sexual disorders
|
JP2008511569A
(ja)
|
2004-09-03 |
2008-04-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
注意欠如活動過多障害の治療方法
|
EP1804778A1
(de)
*
|
2004-10-18 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
|
JP2008531714A
(ja)
*
|
2005-03-04 |
2008-08-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
不安障害の治療用及び/又は予防用の医薬組成物
|
WO2006096439A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
WO2006096435A1
(en)
*
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of depression
|
WO2006119884A2
(en)
*
|
2005-05-06 |
2006-11-16 |
Boehringer Ingelheim International Gmbh |
Method for the treatment of drug abuse with flibanserin
|
US20060258640A1
(en)
*
|
2005-05-13 |
2006-11-16 |
Boehringer Ingelheim International Gmbh |
Use of Flibanserin in the treatment of chronic pain
|
EP1888070A1
(en)
*
|
2005-05-19 |
2008-02-20 |
Boehringer Ingelheim International GmbH |
Method for the treatment of sexual dysfunctions due to medical conditions
|
EP1888071A1
(en)
*
|
2005-05-19 |
2008-02-20 |
Boehringer Ingelheim International GmbH |
Method for the treatment of drug-induced sexual dysfunction
|
EP1896002A4
(en)
|
2005-06-27 |
2009-11-25 |
Biovail Lab Int Srl |
BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
|
US8227476B2
(en)
|
2005-08-03 |
2012-07-24 |
Sprout Pharmaceuticals, Inc. |
Use of flibanserin in the treatment of obesity
|
HU227490B1
(en)
|
2005-08-26 |
2011-07-28 |
Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag |
Sustained release pharmaceutical preparation containing carvedilol
|
JP2009513604A
(ja)
*
|
2005-10-29 |
2009-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
|
US20070123540A1
(en)
*
|
2005-10-29 |
2007-05-31 |
Angelo Ceci |
Sexual desire enhancing medicaments comprising benzimidazolone derivatives
|
US20070105869A1
(en)
*
|
2005-11-08 |
2007-05-10 |
Stephane Pollentier |
Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
|
CN101410093A
(zh)
|
2006-01-27 |
2009-04-15 |
欧兰德股份有限公司 |
包含弱碱性药物和有机酸的药物递送系统
|
US20090023712A1
(en)
*
|
2006-02-18 |
2009-01-22 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
|
US20090176698A1
(en)
*
|
2006-02-20 |
2009-07-09 |
Boehringer Ingelheim International Gmbh |
Benzimidazolone Derivatives for the Treatment of Urinary Incontinence
|
US20090247546A1
(en)
*
|
2006-02-28 |
2009-10-01 |
Boehringer Ingelheim International Gmbh |
Treatment of Prevention of Valvular Heart Disease with Flibanserin
|
WO2007128802A2
(en)
*
|
2006-05-09 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
Use of flibanserin for the treatment of post-menopausal sexual desire disorders
|
WO2008000760A1
(en)
|
2006-06-30 |
2008-01-03 |
Boehringer Ingelheim International Gmbh |
Flibanserin for the treatment of urinary incontinence and related diseases
|
US20090318469A1
(en)
|
2006-07-14 |
2009-12-24 |
Boehringer Ingelheim International Gmbh |
Use of Flibanserin for the Treatment of Sexual Disorders in Females
|
EP2043649A2
(en)
|
2006-07-14 |
2009-04-08 |
Boehringer Ingelheim International GmbH |
Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
|
CL2007002214A1
(es)
*
|
2006-08-14 |
2008-03-07 |
Boehringer Ingelheim Int |
Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
|
KR20090042967A
(ko)
*
|
2006-08-14 |
2009-05-04 |
베링거 인겔하임 인터내셔날 게엠베하 |
플리반세린 제형 및 이의 제조방법
|
AR062321A1
(es)
|
2006-08-25 |
2008-10-29 |
Boehringer Ingelheim Int |
Sistema de liberacion controlada y metodo para fabricarlo
|
EP2097389B1
(en)
|
2006-12-20 |
2011-09-14 |
Boehringer Ingelheim International GmbH |
Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
|
US20100093754A1
(en)
|
2007-03-28 |
2010-04-15 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders
|